换一批
换一批Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
第一作者：
Brian I,Rini
第一单位：
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA. rinib2@ccf.org
作者：
主题词
投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);血管生成抑制剂(Angiogenesis Inhibitors);抗体, 单克隆(Antibodies, Monoclonal);癌, 肾细胞(Carcinoma, Renal Cell);无病生存(Disease-Free Survival);用药计划表(Drug Administration Schedule);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);人类(Humans);吲哚类(Indoles);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);妊娠蛋白质类(Pregnancy Proteins);前瞻性研究(Prospective Studies);吡咯类(Pyrroles);时间因素(Time Factors);治疗失败(Treatment Failure);美国(United States);血管内皮生长因子A(Vascular Endothelial Growth Factor A);血管内皮生长因子C(Vascular Endothelial Growth Factor C);血管内皮生长因子受体3(Vascular Endothelial Growth Factor Receptor-3)
DOI
10.1200/JCO.2007.15.5416
PMID
18669461
发布时间
2022-04-19
- 浏览4
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
